Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. September 2024 08:00 ET | Quelle: Upstream Bio, Inc.

Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress

Upstream gives oral presentation of clinical data for verekitug in patients with severe asthma at European Respiratory Society congress
22. Mai 2024 11:15 ET | Quelle: Upstream Bio, Inc.

Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference

Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
15. Mai 2024 07:00 ET | Quelle: Upstream Bio, Inc.

Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference

Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference